Please ensure Javascript is enabled for purposes of website accessibility

3 Tough Questions for Amgen

By Keith Speights - Feb 15, 2018 at 7:34AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

How successful will Amgen be in the future? Its answers to these three questions provide insight.

After years of rapid revenue and earnings growth for Amgen (AMGN -0.30%), the big biotech experienced a slowdown in 2017. In the fourth quarter, for example, Amgen's revenue and adjusted net income dropped 3% year over year.

Amgen CFO David Meline acknowledged in his comments at the Leerink Partners Global Healthcare Conference on Wednesday that the company is "in a period of transition right now" for several of its key products. Meline sat down for a half-hour question-and-answer session at the Leerink conference. Here are his responses to three tough questions asked at the event. 

Three large question marks on colored sheets of paper

Image source: Getty Images.

1. Can Amgen maintain its high margins?

Just a few years ago, Amgen's operating margin stood around 38%. The biotech's operating margin was nearly 54% in 2017. But can Amgen keep its margins at such a high level?

Meline didn't exactly answer the question, but he did say that the company "certainly expects to have good margins going forward." He pointed to the success of Amgen's initiatives to operate more efficiently. Meline stated that the company sees additional opportunities to improve efficiencies, particularly by implementing next-generation manufacturing capabilities.  

He also said that Amgen will continue to evaluate the best way to develop and commercialize new products on a case-by-case basis as a way to deliver attractive margins. Meline noted the biotech's history of partnering and outlicensing international commercialization rights.

Meline cited Amgen's decision to partner with Novartis (NVS 0.40%) on migraine drug Aimovig. Teaming up with Novartis made sense, according to Meline, because Amgen didn't have experience in neuroscience, while Novartis did. 

2. What will the company do with its cash?

Pretty much every time an Amgen executive speaks to analysts, the question about how the biotech will allocate its capital comes up. It did again at the Leerink conference this week. That's to be expected when a company has nearly $42 billion in cash (including cash, cash equivalents, and marketable securities) socked away.

Meline acknowledged that large cash stockpile, adding that Amgen also generates free cash flow upwards of $10 billion annually. He said this gives the company significant financial flexibility. But what will Amgen do with that financial flexibility?

The biotech will continue to expand its portfolio of products that are substantially differentiated in the market, said Meline. This includes investing internally in research and development. Last year, Amgen poured more than $3.5 billion into R&D. It also includes looking outside of Amgen. Meline noted that "lots of innovation occurs externally," adding that Amgen is "interested in pursuing" those opportunities.

He reiterated Amgen CEO Bob Bradway's comments earlier this year that the company is primarily looking for acquisitions and assets that fit within its six current therapeutic areas of focus. The biotech is also seeking opportunities to expand globally.

Could Amgen potentially make a large acquisition? Meline said that the company needs "to look at entire landscape of possibilities," adding that Amgen "owe[s] it to shareholders" to do so.

In addition, Meline stated that Amgen is committed to returning excess cash to shareholders. He said that there's "no point to sit with a balance sheet with unused financial flexibility."  

3. How will Amgen navigate the challenging payer environment?

Cholesterol drug Repatha hasn't been the success story yet that Amgen had hoped it would be. The biggest reason behind this has been resistance by payers to cover the high-priced drug. With FDA approval for migraine drug Aimovig anticipated by May 17, 2018, how will Amgen navigate the challenging payer environment?

Meline's response was that the company first needed to "offer a good value proposition." He said that achieving that goal would enable Amgen to be successful over time to expand patient access.

He pointed to Prolia as an example of how the company can be successful. The osteoporosis drug started with a "gradual uptake curve," according to Meline. Now, sales for Prolia are growing at 20% or more annually. Meline said that Amgen is confident of its chances for success and is "realistic about what it will take to win."

Looking ahead

Amgen's challenges from 2017 aren't going away this year. The company continues to face headwinds for several of its top products, especially Enbrel and Neulasta. How well Amgen performs will depend to a large extent on whether the company can deliver on David Meline's answers to the last two questions above.

Meline was right that Amgen has seen considerable success with Prolia. The company needs to see similar trajectories for Repatha and Aimovig to return to solid growth. Winning over payers will be a must. Partnering with Novartis on Aimovig was also a smart move, and should help ensure success for the promising migraine drug.

The big biotech could also benefit from a smart acquisition or two. As Meline stated, Amgen has the financial flexibility to do pretty much any size deal. I look for some action from the company on the acquisitions front in 2018. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$246.25 (-0.30%) $0.73
Novartis AG Stock Quote
Novartis AG
NVS
$85.57 (0.40%) $0.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.